Detection of neutralizing antibodies on anti-SARS-CoV2 vaccinated healthcare professionals
DOI:
https://doi.org/10.24265/horizmed.2021.v21n3.02Keywords:
Neutralizing antibodies, Coronavirus infections, Immunogenicity, Vaccination, Health personnelAbstract
Objective: To describe the presence and the concentration of neutralizing antibodies at serum of healthcare professionals inoculated with the Sinopharm anti-SARS-CoV2 vaccine. Materials and methods: Descriptive and transversal research. A total of 117 healthcare professionals inoculated with two doses of the Sinopharm vaccine having quantitative data of neutralizing antibodies at serum (detected by eCLIA) were included. Age, sex, neutralizing antibodies concentration and previous diagnostic of COVID-19 diseases were the variables. Results: A significant increase on neutralizing antibodies concentration were detected on pre- COVID-19 vaccinated persons regarding those vaccinated without previous diagnostic of the viral infection (p < 0,001). Conclusions: the study evidence that Sinopharm vaccine boost immunity against the new coronavirus on previously infected persons and suggest that a third dose of the vaccine could be relevant to boost the immune response.
Downloads
References
Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020; 883: 173375.
He F, Deng Y, Li W. Coronavirus disease 2019: What we know?. J Med Virol. 2020; 92(7): 719-25.
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021; 21(6): 382-93.
Forni G, Mantovani A, COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021; 28(2): 626-39.
Hofman K, Shenoy GN, Chak V, Balu-Iyer SV. Pharmaceutical aspects and clinical evaluation of COVID-19 vaccines. Immunol Invest. 2021; 1-37.
Kyriakidis NC, López-Cortés A, Vásconez Gonzáles E, SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021; 6(1): 28.
Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci. 2021; 17(1): 8-19.
Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect Dis Ther. 2020; 9(2): 1-20.
Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021; 222: 108634.
Colegio Médico del Perú. Vacunómetro-CMP [Internet]. Lima: CMP; 2021. Disponible en: https://www.cmp.org.pe/vacunometro-cmp/
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021; 21(1): 39-51.
World Health Organization. The Sinopharm COVID-19 vaccine: what you need to now [Internet]. WHO; 2021. Disponible en: https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020; 182(3): 713-21.e9.
Murin CD, Wilson IA, Ward AB. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nat Microbiol. 2019; 4(5): 734-47.
Sommerstein R, Fux CA, Vuichard-Gysin D, Abbas M, Marschall J, Balmelli C, et al. Risk of SARS-CoV-2 transmission by aerosols, the rational use of masks, and protection of healthcare workers from COVID-19. Antimicrob Resist Infect Control. 2020; 9(1): 100.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-42.
Ministerio de Salud. Campaña Nacional de Vacunación contra la COVID-19 [Internet]. MINSA: Lima; 2021. Disponible en: https://www.gob.pe/institucion/pcm/campa%C3%B1as/3451-campana-nacional-de-vacunacion-contra-la-covid-19
Mallapaty S. China’s COVID vaccines are going global - but questions remain. Nature. 2021; 593(7858): 178-9.
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020; 586(7830): 594-9.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275): 671-81.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
